The Sjogren’s Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
As per DelveInsight assessments, the Sjogren’s syndrome (SS) market size in the 7MM was found to be USD 1,731.8 Million in 2020. Among 7MM, the United States accounts for the highest market size of Sjogren’s syndrome in comparison with EU5 and Japan. In EU5, the market size of SS in the UK was the highest in 2020, while Spain had the lowest market size for Sjögren’s syndrome. The market size in Japan was found to lowest as compared to US and EU5.
Sjogren’s Syndrome: An Overview
Sjogren’s syndrome is a chronic autoimmune rheumatic disease with a specific predisposition for causing inflammation of the exocrine glands, predominantly the salivary and lacrimal glands, including the nose, upper respiratory tract, and oropharynx. The immune system inappropriately attacks various cells which leads to activation of the various pathway, which results in inflammation.
Despite its considerable prevalence, Sjogren’s syndrome has been devoted much less research interest, time, and effort compared with other close conditions. Various multicenter consortium initiatives have increased awareness for Sjogren’s Syndrome leading to defining key areas of development, ultimately leading to improved patient care.
Sjogren’s Syndrome Market Key Facts
-
As per DelveInsight estimates, the total cases of Sjogren’s syndrome (SS) in the 7MM were found to be 3,233,800+ in 2020.
-
Among all the countries, the United States accounts for a higher population of Sjogren’s syndrome (SS) with 1,731,700+ cases in 2020.
-
Among the EU5 countries, the UK had the highest diagnosed prevalent population of Sjögren’s syndrome followed by Germany. On the other hand, Spain had the lowest prevalent population.
-
Females are more prone to SS than males in all countries. In 2020, there were 173,100+ prevalent cases of Sjögren’s syndrome in males and 1,558,600+ prevalent cases in females in the US and as per analysts’ assessments, the overall cases of SS in both the genders are subjected to increase in the coming years with increasing population.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Sjogren’s Syndrome market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Sjogren’s Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Sjogren’s Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Sjogren’s Syndrome Epidemiology Subtype Segmentation
-
Total Diagnosed Prevalent Cases of Sjogren’s syndrome
-
Gender-specific Cases of Sjogren’s syndrome
-
Type-Specific Cases of Sjogren’s syndrome
-
Type-Specific Cases of Sjogren’s syndrome
Sjogren’s Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sjogren’s Syndrome market or expected to get launched during the study period. The analysis covers Sjogren’s Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Sjogren’s Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size
Sjogren’s Syndrome Therapeutics Analysis
Several companies are working robustly on developing many new therapies for the treatment of Sjogren’s syndrome. The mid-stage pipeline is crowded, with several potential therapies with the imminent attention of big pharmaceutical companies.
Some of the key companies in the Sjogren’s Syndrome Market include:
-
Roche
-
Novartis
-
Viela Bio
-
Immupharma
-
TearSolutions
-
GlaxoSmithKline
-
Resolve Therapeutics
-
Novartis/MorphoSys
-
Gilead Sciences
-
Bristol Myers Squibb
And others.
Sjogren’s Syndrome Therapies covered in the report include:
-
VIB7734
-
VAY736
-
Belimumab
-
RSLV-132
-
CFZ533
-
LOU-064
-
GS-9876
-
Lacripep
-
Abatacept
-
RO5459072
And many more.
As per DelveInsight, the launch of the emerging therapies is expected to change the therapeutic market dynamics.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Sjogren’s Syndrome Competitive Intelligence Analysis
4. Sjogren’s Syndrome Market Overview at a Glance
5. Sjogren’s Syndrome Disease Background and Overview
6. Sjogren’s Syndrome Patient Journey
7. Sjogren’s Syndrome Epidemiology and Patient Population
8. Sjogren’s Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Sjogren’s Syndrome Unmet Needs
10. Key Endpoints of Sjogren’s Syndrome Treatment
11. Sjogren’s Syndrome Marketed Products
12. Sjogren’s Syndrome Emerging Therapies
13. Sjogren’s Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Sjogren’s Syndrome Market Outlook (7 major markets)
16. Sjogren’s Syndrome Access and Reimbursement Overview
17. KOL Views on the Sjogren’s Syndrome Market.
18. Sjogren’s Syndrome Market Drivers
19. Sjogren’s Syndrome Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Varicose Veins Market
“Varicose Veins Market” report delivers an in-depth understanding of the Varicose Veins, historical and forecasted epidemiology as well as the Varicose Veins market trends in 7MM.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/